Drug intelligence / Profile preview

CalmIV-E

Development stage
Unknown
Lead developer
El Dorado Bio Tech
Modality
Small Molecules
Administration
Oral
01

Overview

CalmIV-E is a branded generic combination medication marketed by Eldora (El-Dorado Biotech) in India, primarily indicated for the management of anxiety disorders and comorbid depression. The drug is composed of two active ingredients: etizolam and escitalopram. Etizolam is a thienodiazepine derivative that acts as a positive allosteric modulator of the GABA-A receptor, facilitating inhibitory neurotransmission to provide rapid-onset anxiolytic, sedative, and muscle relaxant effects. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin levels by inhibiting the serotonin transporter (SERT), thereby addressing underlying depressive symptoms. This combination is frequently utilized in clinical practice to manage patients who require both immediate relief from acute anxiety and long-term stabilization of mood.

Brand names
CalmIV-E
Other names
CalmIV-E-EldoraCalmIV-E SEMI
02

Targets

SERT (Sodium-dependent serotonin transporter)GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)

Beyond the preview

Go deeper on CalmIV-E.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CalmIV-E.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call